Admission Management Software Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The adrenal cancer diagnostics market size has grown strongly in recent years. It will grow from $140.35 billion in 2024 to $149.96 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increased incidence and awareness, genetic and molecular testing advances, biopsy techniques improvement, enhanced endocrine testing, integration of artificial intelligence (ai).

The adrenal cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $193.26 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine approaches, rise in minimally invasive procedures, telemedicine and remote consultations, liquid biopsy development, expanded genetic counseling services. Major trends in the forecast period include regulatory support for diagnostic innovations, digital pathology adoption, advancements in imaging technologies, liquid biopsy development, genomic profiling for precision medicine.

The anticipated rise in cigarette smoking is poised to drive the growth of the adrenal cancer diagnostics market. Cigarette smoking involves inhaling and exhaling fumes from burning tobacco containing nicotine, an addictive alkaloid with psychoactive effects. Adrenal cancer, including adenomas and adrenocortical carcinomas, has been linked to increased risks associated with cigarette smoking. The carcinogens in tobacco smoke can lead to DNA damage in adrenal cells, resulting in mutations that may cause cancer. Notably, Statistics Canada reported a 5.8% increase in cigarette production in July 2022 compared to June 2021, with the total number of cigarettes sold reaching 1.4 billion in June 2022. Thus, the growing prevalence of cigarette smoking is a key driver for the adrenal cancer diagnostics market.

Government initiatives supporting cancer are expected to propel the growth of the adrenal cancer diagnostics market. These initiatives involve significant actions taken by governments to address challenges, improve diagnostic services' quality and accessibility, and support research for effective adrenal cancer diagnostics. In April 2023, the Biden-Harris administration, as per the National Institutes of Health (NIH), established an initiative to reduce cancer-related deaths by 50% within 25 years while enhancing support for individuals enduring and surviving cancer. Government initiatives contribute significantly to driving the growth of the adrenal cancer diagnostics market.

Leading companies in the adrenal cancer diagnostics market are launching innovative initiatives through advanced collaboration models, such as the CancerX Startup Accelerator, to boost digital innovations in cancer care. This Accelerator is designed to offer promising startups mentorship, training, and direct connections to key stakeholders in the healthcare sector, including providers and pharmaceutical firms. For instance, in November 2023, CanceRx, LLC, a US-based public-private partnership aimed at enhancing innovation in the fight against cancer, announced the launch of this initiative during the Future of Cancer Care Summit held in Tampa, Florida. The program plans to select its first cohort of about 15 to 20 companies starting in March 2024, concentrating on critical themes such as clinical research, screening, diagnosis, and treatment. It is anticipated that this initiative will significantly advance the objectives of the Cancer Moonshot initiative by tackling unmet needs in cancer care and promoting the development of effective digital health tools in oncology.

In June 2023, Quest Diagnostics, a US-based medical laboratory company, acquired Haystack Oncology, Inc. for an undisclosed sum. As a result of this acquisition, Quest Diagnostics will integrate Haystack Oncology’s minimal residual disease (MRD) testing technology, which is based on circulating tumor DNA (ctDNA). Haystack Oncology, Inc. is a biotechnology company located in the United States.

Major companies operating in the adrenal cancer diagnostics market report are Johnson And Johnson Pvt Ltd., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, GSK PLC, AstraZeneca PLC, Abbott Laboratories, Siemens Healthcare GmbH, Becton Dickinson and Company, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies, Hologic Inc., PerkinElmer Inc., Illumina Inc., Roche Diagnostics, BioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Exact Sciences Corp., Natera Inc., Invitae Corporation, Qiagen NV, Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., TRS Technologies Inc., Morgan Advanced Materials, APC International Ltd., Annon Piezo Technology Co. Limited.

North America was the largest region in the adrenal cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenal cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adrenal cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adrenal cancer diagnostics market consists of revenues earned by entities by providing genetic testing, histopathology, blood tests, and dexamethasone suppression tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenal cancer diagnostics market also includes sales of ultrasound machines, reagents and test kits, microscopes, histology kits, and microtomes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Adrenal cancer diagnostics involve the identification and detection of cancer originating in the adrenal glands, situated above the kidneys. This process encompasses a series of medical assessments, tests, and procedures designed to establish the presence of adrenal cancer, playing a crucial role in effective treatment planning and management.

The primary diagnostic tests for adrenal cancer include magnetic resonance imaging (MRI), computed tomography (CT) scans, X-rays, positron emission tomography (PET) scans, and biopsies. Magnetic resonance imaging (MRI) is a medical imaging technique that utilizes strong magnetic fields and radio waves to generate detailed and high-resolution images of the body's internal structures. Treatment modalities encompass surgery, chemotherapy, radiotherapy, targeted cancer therapies, and others tailored for pheochromocytoma, adrenal cortical carcinoma, and various tumor types. These treatments are administered by diverse end-users such as hospitals, ambulatory surgical centers, cancer centers, and others.

The adrenal cancer diagnostics market research report is one of a series of new reports that provides adrenal cancer diagnostics market statistics, including adrenal cancer diagnostics industry global market size, regional shares, competitors with an adrenal cancer diagnostics market share, detailed adrenal cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the adrenal cancer diagnostics industry. This adrenal cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.